Viral Vector– tag –
-
European Biotechs Unveil Next-Gen CGT Manufacturing to Cut CAR-T Costs Above €60,000 Per Patient
PharmTech Global Overview European biopharmaceutical companies are spearheading the development of advanced manufacturing technologies to address the high costs and logistical hurdles of Cell and Gene Therapies (CGT). Innovations include... -
KATU News: Experimental Gene Therapy Targeting Aging Cells Based on Yamanaka Factors Enters Early Glaucoma Trials
KATU News (YouTube) USA Overview According to KATU News, an experimental gene therapy inspired by Professor Shinya Yamanaka's Nobel Prize-winning iPSC research is targeting aging cells and holds the potential to open a new chapter in agi... -
Europe’s Biotech Vanguard: Automated, Closed Systems Drive Next-Gen CGT Manufacturing and Decentralized Access
PharmTech.com ヨーロッパ Overview European biotechnology firms are pioneering next-generation manufacturing technologies for cell and gene therapies (CGT), centered on automated, closed systems. These innovations, exemplified by companie... -
FDA Approves Allogeneic Cell Therapy TREGZI for GVHD; New Advanced Cell Therapy Association Launches in Europe
RegMedNet UK Overview The FDA has approved Orca Bio's allogeneic cell therapy TREGZI (Orc-T®) for graft-versus-host disease (GVHD), based on positive Phase 3 Precision-T trial results, aiming to mitigate GVHD and reconstruct immunity. Si... -
SK pharmteco Unveils SKyvec™ Viral Vector Platform, Boosting AAV Productivity by 5-6 Fold for Gene Therapy Development
Contract Pharma Global Overview SK pharmteco has launched its innovative 'SKyvec™ Viral Vector Platform,' designed to accelerate gene therapy development. This platform supports adeno-associated virus (AAV), lentivirus, and adenovirus ve... -
European Biotechs Lead Next-Gen Cell & Gene Therapy Manufacturing Innovation: From Scalable Stem Cells to Clinical CAR Treg Trials
PharmTech ヨーロッパ Overview European biotech companies are pioneering next-generation manufacturing technologies crucial for the commercial viability and accessibility of cell and gene therapies (CGTs), prioritizing scalable allogeneic... -
Engineered Allogeneic Treg Cell Therapy TRX103 Enters Phase 1/2a Clinical Trials for Crohn’s Disease and GvHD Prevention
Frontiers Global Overview The gene-edited allogeneic Treg cell therapy candidate TRX103, designed as a scalable, off-the-shelf application, has commenced Phase 1/2a clinical evaluation for Crohn's disease and Graft-versus-Host Disease (G... -
Genedata Establishes New Standard for Biopharma Quality Control with NGS, Ensuring Genetic Stability in CGT
Genedata Switzerland Overview Genedata highlights Next-Generation Sequencing (NGS) as a powerful analytical tool for biopharmaceutical quality control (QC). NGS offers GxP-compliant workflows and supports data integrity and streamlined c... -
Orchestrating the Next Era of Decentralized and Automated Bioprocessing: 75% Efficiency Boost in AAV Manufacturing and QC Modernization
BioPharm International USA Overview BioPharm International discussed orchestrating the next era of the biopharmaceutical industry through decentralized manufacturing models, automated AAV manufacturing, and modernizing quality control (Q... -
Advancing Cell Therapy Production: CCRM, OmniaBio, and Avectas Pioneer Automated Hub-and-Spoke Model for CAR-T, iPSC, and Lentiviral Vectors
PR Newswire (CCRM) Canada, アイルランド Overview CCRM and its CDMO subsidiary, OmniaBio, have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This strategic alliance ...
